ESMO Congress 2026

Ribociclib is a CDK4/6 inhibitor, a class whose position in HR-positive, HER2-negative advanced breast cancer was established by a series of phase 3 trials: first-line ribociclib plus letrozole significantly improved investigator-assessed progression-free survival in 668 postmenopausal patients ^[1]; combined with fulvestrant, median progression-free survival was extended from 12.8 to 20.5 months (HR 0.593) ^[3]; MONALEESA-7 in premenopausal women also confirmed efficacy ^[4] and further showed an overall survival benefit, with death rates of 24.8% versus 32.3% ^[5]; the final overall survival analysis of the first-line regimen after a median follow-up of 6.6 years was likewise significant, with deaths in 54.2% versus 65.6% ^[6]. This asset thus already carries dual PFS and OS evidence in the advanced setting, with abemaciclib and palbociclib as other agents in the class ^[2].

What was reported at ESMO26 is a different trial: adjuvant ribociclib plus endocrine therapy after surgery in high-risk, HR-positive, HER2-negative early breast cancer, with 6 years of follow-up and all patients off ribociclib. The figures from the floor: the iDFS benefit was maintained with a difference of 5.3%; OS was favorable with a difference of 2.1%; the risk of death was reduced by about 20%, the OS improvement was statistically significant, and the benefit persisted after the end of treatment. The same post also stated that efficacy is comparable to abemaciclib (monarchE), with a different toxicity profile and a wider population (N+ and high-risk N0) — a cross-trial comparison that stands alongside, and should not be conflated with, the main trial update.

Relative to existing knowledge, this readout advances the picture in three ways. First, ribociclib's previous survival evidence all came from the advanced or metastatic setting ^[5][6], and this brings the survival benefit signal into the curative-intent adjuvant setting. Second, with all patients already off treatment, the iDFS and OS differences were still maintained at 5.3% and 2.1%, suggesting durability of benefit after treatment ends. Third, the covered population extends to high-risk node-negative patients, beyond node-positive only, echoing the wider population emphasized in the post.

Limitations should also be noted: the claimed comparability with monarchE is an indirect comparison made at the conference, not a head-to-head trial; the post did not disclose sample size, subgroup details, or specific safety data, and how the toxicity profile differs was not elaborated — details beyond the differences above await confirmation with full publication.